Skip to Main Content

Paper Details

A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia.
Haematologica
10
2022
Author NameAffiliation
Martin S TallmanMemorial Sloan Kettering Cancer Center, Weill Cornell Medical College
  • 1 - 1

Datasets

Release 1.2